Analyst: Obesity market could surpass USD 70bn by 2030
Novo Nordisk is aiming to sell obesity drugs for over DKK 25bn (USD 3.7bn) in 2025, and one analyst says the market could be 20 times bigger at DKK 500bn (USD 73.8bn) by 2030 if treatment lasts two years.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Should Novo Nordisk and Eli Lilly manage to get 10 million of 17 million Americans with severe obesity into medical treatment lasting at least two years, the obesity drug market could surpass DKK 500bn (USD 73.8bn) by 2030, according to Wimal Kapadia, biopharma equity research at Sanford C. Bernstein, as reported by Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo CFO: Obesity market is difficult to predict
For subscribers
Novo Nordisk more than doubles 2025 obesity sales goal
For subscribers
